📰 Curated Industry Article
This is a summary of a full article from a trusted healthcare and insurance publication. Click “Read Full Article” below to read the complete story.
DreaMed Diabetes has received FDA 510(K) clearance for MODI, a mobile app that uses CGM (continuous glucose monitoring) data to provide insulin dosing recommendations for people with Type 2 diabetes who need both basal insulin and fast-acting injections.
The post DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens appeared first on MedCity News.
💡 What This Means For You
[armfox_dynamic_insight]
ARMFOX HEALTHCARE
Stay Informed. Protect Your Future.
No pressure. No jargon. Just honest answers from advisors who genuinely care about your family’s protection.
📰 This article is sourced from a trusted healthcare and insurance industry publication. Armfox Healthcare shares this for informational purposes only. Always consult a licensed advisor for personalized guidance.